JP2020518289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518289A5 JP2020518289A5 JP2020512082A JP2020512082A JP2020518289A5 JP 2020518289 A5 JP2020518289 A5 JP 2020518289A5 JP 2020512082 A JP2020512082 A JP 2020512082A JP 2020512082 A JP2020512082 A JP 2020512082A JP 2020518289 A5 JP2020518289 A5 JP 2020518289A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- isolated
- amplified
- culturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 173
- 238000000034 method Methods 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 38
- 238000012258 culturing Methods 0.000 claims description 25
- 230000003321 amplification Effects 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 15
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 claims description 11
- 230000003394 haemopoietic effect Effects 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002335 Interleukin-9 Proteins 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 description 11
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 11
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 9
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 9
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 6
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 5
- 102100022341 Integrin alpha-E Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 102100025221 CD70 antigen Human genes 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 4
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 4
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
- 239000003550 marker Substances 0.000 description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023022974A JP7698672B2 (ja) | 2017-05-03 | 2023-02-17 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
| JP2025099083A JP2025134795A (ja) | 2017-05-03 | 2025-06-13 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1707048.3 | 2017-05-03 | ||
| GBGB1707048.3A GB201707048D0 (en) | 2017-05-03 | 2017-05-03 | Expansion of gamma delta cells, compositions, and methods of use thereof |
| PCT/EP2018/061413 WO2018202808A2 (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta t cells, compositions, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023022974A Division JP7698672B2 (ja) | 2017-05-03 | 2023-02-17 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518289A JP2020518289A (ja) | 2020-06-25 |
| JP2020518289A5 true JP2020518289A5 (OSRAM) | 2021-06-17 |
Family
ID=59010925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512082A Pending JP2020518289A (ja) | 2017-05-03 | 2018-05-03 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
| JP2023022974A Active JP7698672B2 (ja) | 2017-05-03 | 2023-02-17 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
| JP2025099083A Pending JP2025134795A (ja) | 2017-05-03 | 2025-06-13 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023022974A Active JP7698672B2 (ja) | 2017-05-03 | 2023-02-17 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
| JP2025099083A Pending JP2025134795A (ja) | 2017-05-03 | 2025-06-13 | ガンマデルタｔ細胞の増幅、組成物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11655453B2 (OSRAM) |
| EP (1) | EP3619298A2 (OSRAM) |
| JP (3) | JP2020518289A (OSRAM) |
| KR (2) | KR102812405B1 (OSRAM) |
| CN (1) | CN110914410A (OSRAM) |
| AU (2) | AU2018262698B2 (OSRAM) |
| BR (1) | BR112019023076A2 (OSRAM) |
| CA (1) | CA3062386A1 (OSRAM) |
| EA (1) | EA201992610A1 (OSRAM) |
| GB (1) | GB201707048D0 (OSRAM) |
| IL (3) | IL270365B2 (OSRAM) |
| MX (2) | MX2019013001A (OSRAM) |
| PH (1) | PH12019502485A1 (OSRAM) |
| WO (1) | WO2018202808A2 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2601896T3 (es) | 2004-11-24 | 2017-02-16 | Fred Hutchinson Cancer Research Center | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| GB201818243D0 (en) * | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3117895A1 (en) | 2018-11-08 | 2020-05-14 | GammaDelta Therapeutics Limited | Methods for isolating and expanding cells |
| CN109517793B (zh) * | 2018-11-30 | 2022-05-10 | 广州长峰生物技术有限公司 | 一种NK细胞和γδT细胞共培养的建立方法 |
| GB201909144D0 (en) * | 2019-06-25 | 2019-08-07 | Autolus Ltd | Culture medium |
| PH12022551009A1 (en) | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| KR20220123652A (ko) * | 2019-12-03 | 2022-09-08 | 아디셋 바이오, 인크. | 다가 제제를 이용하여 γδ T-세포 집단을 확장시키는 방법 및 이의 조성물 |
| US20210290674A1 (en) * | 2020-03-20 | 2021-09-23 | GammaDelta Therapeutics Ltd. | Methods for treating myeloid malignancies |
| AU2020436661A1 (en) | 2020-03-20 | 2022-11-10 | GammaDelta Therapeutics Limited | V Delta1+ T cells for the treatment of myeloid malignancies |
| GB202006989D0 (en) | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| GB202013962D0 (en) * | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
| CN113234675A (zh) * | 2021-03-31 | 2021-08-10 | 广西医科大学 | 一种γδT细胞以及采用体外制备γδT细胞的方法 |
| GB202105113D0 (en) * | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| WO2022221439A1 (en) * | 2021-04-14 | 2022-10-20 | The Trustees Of The University Of Pennsylvania | Methods to determine treatment efficacy with gamma-delta t cells |
| EP4322972A4 (en) * | 2021-04-16 | 2025-03-12 | Acepodia Biotechnologies Ltd. | Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof |
| CA3235971A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
| US20250066477A1 (en) * | 2022-01-05 | 2025-02-27 | Inhibrx Biosciences, Inc. | Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof |
| EP4680729A1 (en) * | 2023-03-17 | 2026-01-21 | Legend Biotech Ireland Limited | Methods of culturing v delta 1 t cells |
| CN120897748A (zh) | 2023-04-07 | 2025-11-04 | 武田药品工业株式会社 | 用于治疗复发性或难治性急性骨髓性白血病的t细胞 |
| WO2025017531A1 (en) | 2023-07-20 | 2025-01-23 | Takeda Pharmaceutical Company Limited | Grid-free methods for making gamma delta t cells |
| CN121909213A (zh) * | 2023-07-26 | 2026-04-21 | 詹森生物科技公司 | 用于细胞生长的材料和方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| DE69940352D1 (de) * | 1998-11-04 | 2009-03-12 | Therapure Biopharma Inc | Verfahren zur herstellung von gamma delta t zellen |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2805971A1 (en) | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| PT2710123T (pt) | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| ES2539845B1 (es) | 2013-08-05 | 2016-04-13 | Universidad De Alicante | Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao |
| CN105848484A (zh) * | 2013-10-25 | 2016-08-10 | 得克萨斯州大学系统董事会 | 用于免疫治疗的多克隆γδ T细胞 |
| US20170107490A1 (en) * | 2014-06-11 | 2017-04-20 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| IL252131B2 (en) * | 2014-11-17 | 2023-04-01 | Adicet Bio Inc | Transgenic gamma delta T cells |
| CN114099793A (zh) * | 2015-04-10 | 2022-03-01 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
| US11166983B2 (en) * | 2015-06-09 | 2021-11-09 | Lymphact—Lymphocyte Activation Technologies, S.A. | Methods for the production of TCRγδ+ T cells |
| WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| CA3003077A1 (en) * | 2015-10-30 | 2017-05-04 | King's College London | Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
-
2017
- 2017-05-03 GB GBGB1707048.3A patent/GB201707048D0/en not_active Ceased
-
2018
- 2018-05-03 IL IL270365A patent/IL270365B2/en unknown
- 2018-05-03 EP EP18725128.5A patent/EP3619298A2/en active Pending
- 2018-05-03 WO PCT/EP2018/061413 patent/WO2018202808A2/en not_active Ceased
- 2018-05-03 AU AU2018262698A patent/AU2018262698B2/en active Active
- 2018-05-03 BR BR112019023076A patent/BR112019023076A2/pt unknown
- 2018-05-03 IL IL319114A patent/IL319114A/en unknown
- 2018-05-03 MX MX2019013001A patent/MX2019013001A/es unknown
- 2018-05-03 US US16/610,398 patent/US11655453B2/en active Active
- 2018-05-03 CA CA3062386A patent/CA3062386A1/en active Pending
- 2018-05-03 KR KR1020197035686A patent/KR102812405B1/ko active Active
- 2018-05-03 KR KR1020257016628A patent/KR20250080907A/ko active Pending
- 2018-05-03 IL IL312633A patent/IL312633B2/en unknown
- 2018-05-03 CN CN201880044728.0A patent/CN110914410A/zh active Pending
- 2018-05-03 JP JP2020512082A patent/JP2020518289A/ja active Pending
- 2018-05-03 EA EA201992610A patent/EA201992610A1/ru unknown
-
2019
- 2019-10-31 MX MX2024004897A patent/MX2024004897A/es unknown
- 2019-11-04 PH PH12019502485A patent/PH12019502485A1/en unknown
-
2023
- 2023-01-12 US US18/153,900 patent/US12458698B2/en active Active
- 2023-02-17 JP JP2023022974A patent/JP7698672B2/ja active Active
-
2025
- 2025-06-13 JP JP2025099083A patent/JP2025134795A/ja active Pending
- 2025-09-10 AU AU2025230679A patent/AU2025230679A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | Gamma delta T cells and their pathogenic role in psoriasis | |
| Peng et al. | Natural killer cell memory: progress and implications | |
| DE102017127984B4 (de) | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen | |
| EP3878950B1 (en) | Method for culturing natural killer cells using t cells | |
| AU2018262698B2 (en) | Expansion of gamma delta T cells, compositions, and methods of use thereof | |
| Hall et al. | Distinct regulatory CD4+ T cell subsets; differences between naïve and antigen specific T regulatory cells | |
| Gao et al. | Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells | |
| Lohmann‐Matthes et al. | Macrophage‐mediated cytotoxicity against allogeneic target cells in vitro | |
| Ciciarello et al. | The yin and yang of the bone marrow microenvironment: pros and cons of mesenchymal stromal cells in acute myeloid leukemia | |
| US11566227B2 (en) | Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same | |
| JP3619853B2 (ja) | ナチュラルキラー細胞の増殖方法 | |
| Choi et al. | The function of memory CD8+ T cells in immunotherapy for human diseases | |
| Yang et al. | Therapeutic application of T regulatory cells in composite tissue allotransplantation | |
| KR101035556B1 (ko) | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물 | |
| Chargui et al. | Bromohydrin pyrophosphate-stimulated Vγ9δ2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells | |
| JP2023514788A5 (OSRAM) | ||
| DE4410136A1 (de) | Tumorizide T-Lymphozyten | |
| Gao et al. | Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease | |
| JP2024539088A5 (OSRAM) | ||
| JP2023525391A (ja) | Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途 | |
| JP2019508056A5 (OSRAM) | ||
| Prosser et al. | Understanding Liver Transplantation Outcomes Through the Lens of Its Tissue-resident Immunobiome | |
| JP2025502150A5 (OSRAM) | ||
| KR20120095320A (ko) | 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물 | |
| Simpson-Abelson et al. | Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process |